<DOC>
	<DOCNO>NCT01855074</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety long act injectable microspheres risperidone participant schizophrenia ( psychiatric disorder symptom emotional instability , detachment reality , often delusion hallucination , withdrawal self ) , schizophreniform schizoaffective disorder ( disorder loss ego boundary gross impairment reality test delusion prominent hallucination ) .</brief_summary>
	<brief_title>An Efficacy Safety Study Risperidone Long-Acting Microspheres Participants With Schizophrenia , Schizophreniform Schizoaffective Disorders</brief_title>
	<detailed_description>This open-label ( people know identity intervention ) , longitudinal ( participant follow time continuous repeat monitoring risk factor health-outcomes ) , non-randomized ( clinical trial participant assign chance different treatment group ) , single-center study evaluate efficacy safety long act microspheres risperidone adult participant schizophrenia , schizophreniform schizoaffective disorder . The duration study 12 month duration treatment 6 month . The study include 4 visit : Baseline , 3 follow-up visit include Week 4 , 12 26 . All eligible participant treat risperidone 25 milligram ( mg ) intramuscular injection ( injection substance muscle ) every two week 6 month . Participants persistent symptom and/or require high dos antipsychotic ( agent control agitate psychotic behavior , alleviate acute psychotic state , reduce psychotic symptom , exert quiet effect ) initiate high dos risperidone . Doses adjust accord response treatment . Efficacy safety participant primarily evaluate Positive Negative Syndromes Scale ( PANSS ) Extrapyramidal Symptom Rating Scale ( ESRS ) , respectively . Participants ' quality life safety monitor throughout study .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<criteria>Symptomatically stable participant define ) participant treatment outpatient inpatient basis least 4 week enter study , b ) Positive Negative Syndrome Scale ( PANSS ) Positive Subscale Score less equal ( &lt; = ) 3 ( 17 ) , include conceptual disorganization , suspicion , hallucinatory conduct delirium ( state violent mental agitation ) Participants antipsychotic treatment extrapyramidal symptom , persistent negative symptom lack adherence define irregular administration medication last 2 week Participants give informed consent writing , least , family member personal representative Participants take first antipsychotic treatment his/her life Participants psychotic disorder different previously mention inclusion criterion Pregnant nursing woman History neuroleptic malignant syndrome ( potentially fatal syndrome associate primarily use antipsychotic drug clinical feature include diffuse muscle rigidity , tremor , high fever ) current symptom tardive dyskinesia ( neurological disorder characterize involuntary movement face jaw ) Participants know intolerance lack response risperidone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Schizophreniform Disorder</keyword>
	<keyword>Schizoaffective Disorder</keyword>
	<keyword>Risperidone</keyword>
	<keyword>Risperdal consta</keyword>
</DOC>